Class III antiarrhythmic activity in vivo by selective blockade of the slowly activating cardiac delayed rectifier potassium current I(Ks) by (R)- 2-(2,4-trifluoromethyl)-N-[2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-2,3- dihydro-1h-benzo[e][1,4]diazepin-3-yl]acetamide

Journal of Medicinal Chemistry

Volumn 40, Issue 24, 1997, Pages 3865-3868

  Selnick, Harold G ^a   Liverton, Nigel J ^a   Baldwin, John J ^a   Butcher, John W ^a   Claremon, David A ^a   Elliott, Jason M ^a   Freidinger, Roger M ^a   King, Stella A ^a   Libby, Brian E ^a   McIntyre, Charles J ^a   Pribush, David A ^a   Remy, David C ^a   Smith, Garry R ^a   Tebben, Andrew J ^a   Jurkiewicz, Nancy K ^a   Lynch, Joseph J ^a   Salata, Joseph J ^a   Sanguinetti, Michael C ^a   Siegl, Peter K S ^a   Slaughter, Donald E ^a   Vyas, Kamlesh ^a   more..

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2,4 TRIFLUOROMETHYL) N [2 OXO 5 PHENYL 1 (2,2,2 TRIFLUOROETHYL) 2,3 DIHYDRO 1H BENZO[E][1,4]DIAZEPIN 3 YL]ACETAMIDE; SODIUM CHANNEL; UNCLASSIFIED DRUG;

ACTION POTENTIAL; ANTIARRHYTHMIC ACTIVITY; ARTICLE; CORONARY ARTERY DISEASE; ELECTROCARDIOGRAM; HEART RHYTHM; HEART VENTRICLE TACHYCARDIA; POTASSIUM CURRENT; REFRACTORY PERIOD; REPOLARIZATION; SUDDEN DEATH;

ACETAMIDES; ADMINISTRATION, ORAL; ANIMALS; ANTI-ARRHYTHMIA AGENTS; BENZODIAZEPINONES; CELLS, CULTURED; DOGS; ELECTROCARDIOGRAPHY, AMBULATORY; GUINEA PIGS; HEART; HUMANS; MYOCARDIUM; POTASSIUM CHANNEL BLOCKERS; POTASSIUM CHANNELS; XENOPUS;

EID: 15144345474     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm970517u     Document Type: Article

References (18)

1. Kerwin, J. F., Jr.; Lancaster, J. R., Jr.; Feldman, P. L. Nitric Oxide: A New Paradigm for Second Messengers. J. Med. Chem. 1995, 38, 4342-4362.
2. Abu-Soud, H. M.; Yoho, L. L.; Stuehr, D. J. Calmodulin Controls Neuronal Nitric Oxide Synthase by a Dual Mechanism. Activation of Intra- and Interdomain Electron Transfer. J. Biol. Chem. 1994, 269, 32047-32050.
3. Kerwin, J. F.; Heller, M. The Arginine-Nitric Oxide Pathway: A Target for New Drugs. Med. Res. Rev. 1994, 14, 23-74.
4. (a) Choi, D. W.; Rothman, S. M. The Role of Glutamate Neurotoxicity in Hypoxic-Ischemic Neuronal Death. Annu. Rev. Neurosci. 1990, 13, 171-182.
5. (b) Garthwaite, J. In The NMDA Receptor; Watkins, J. C., Collingridge, G. L., Eds.; Oxford University Press: Oxford, England, 1989; pp 187-205.
6. (c) Shibuki, K. Nitric Oxide, an Intracellular Messenger in Cerebellar Synaptic Plasticity. Biomed. Res. 1994, 15, 65-67.
7. (d) Dalkara, T.; Yoshida, T.; Irikura, K.; Moskowitz, M. A. Dual Role of Nitric Oxide in Focal Cerebral Ischemia. Neuropharmacology 1994, 33, 1447-1452.
8. (e) Bredt, D. S.; Snyder, S. H. Nitric Oxide, a Novel Neuronal Messenger. Neuron 1992, 8, 3-11.
9. Petros, A.; Bennett, D.; Vallance, P. Effect of Nitric Oxide Synthase Inhibitors on Hypotension in Patients with Septic Shock. Lancet 1991, 338, 1557.
10. Maclntyre, I.; Zaidi, M.; Towhidul Alam, A. S. M.; Datta, H. K.; Moonga, B. S.; Lidbury, P. S.; Hecker, M.; Vane, J. R. Osteoclastic Inhibition: An Action of Nitric Oxide Not Mediated by Cyclic GMP. Proc. Natl. Acad. Sci. U.S.A. 1991, 88, 2936-2940.
11. Seo, H. G.; Takata, I.; Nakamura, M.; Tatsumi, H.; Suzuki, K.; Fujii, J.; Taniguchi, N. Induction of Nitric Oxide Synthase and Concomitant Suppression of Superoxide Dismutases in Experimental Colitis in Rats. Arch. Biochem. Biophys. 1995, 324, 41-47.
12. Marietta, M. A. Approaches toward Selective Inhibition of Nitric Oxide Synthase. J. Med. Chem. 1994, 37, 1899.
13. Moore, W. M.; Webber, R. K.; Fok, K. F.; Jerome, G. M.; Kornmeier, C. M.; Tjoeng, F. S.; Currie, M. G. Inhibitors of Human Nitric Oxide Synthase Isoforms with the Carbamidine Moiety as a Common Structural Element. Bioorg. Med. Chem. 1996, 4, 1559-1564.
14. Zhang, H. Q.; Dixon, R. P.; Marletta, M. A.; Nikolic, D.; Van Breemen, R.; Silverman, R. B. Mechanism of Inactivation of Neuronal Nitric Oxide Synthase by Nω-Allyl-L-arginine. J. Am Chem. Soc. 1997, 119, in press.
15. The competitive reversible inhibition of the isoforms by Nω-propyl-L-arginine was studied under initial rate conditions with the hemoglobin assay as described in ref 10. The concentrations of L-arginine used were 3, 4, 6, 10, and 15 μM for nNOS; 10, 20, 30, and 60 μM for iNOS; and 2, 4, 8, and 15 μM for eNOS, The concentrations of Nμ-propyl-L-arginine used were 0.05, 0.1, 0.15, and 0.2 μM for nNOS; 50, 100, 150, and 200 μM for iNOS; and 10, 20, 30, and 40 μM for eNOS. Data were analyzed by the methods of Dixon (Dixon, M. The determination of enzyme inhibitor constants. Biochem. J. 1953, 55, 170-171) and Cornish-Bowden (Cornish-Bowden, A. Fundamentals of Enzyme Kinetics; Portland Press: London, 1995; pp 102-108).
16. The competitive reversible inhibition of the isoforms by Nω-propyl-L-arginine was studied under initial rate conditions with the hemoglobin assay as described in ref 10. The concentrations of L-arginine used were 3, 4, 6, 10, and 15 μM for nNOS; 10, 20, 30, and 60 μM for iNOS; and 2, 4, 8, and 15 μM for eNOS, The concentrations of Nμ-propyl-L-arginine used were 0.05, 0.1, 0.15, and 0.2 μM for nNOS; 50, 100, 150, and 200 μM for iNOS; and 10, 20, 30, and 40 μM for eNOS. Data were analyzed by the methods of Dixon (Dixon, M. The determination of enzyme inhibitor constants. Biochem. J. 1953, 55, 170-171) and Cornish-Bowden (Cornish-Bowden, A. Fundamentals of Enzyme Kinetics; Portland Press: London, 1995; pp 102-108).
17. Hevel, J. M.; White, K. A.; Marletta, M. A. Purification of the Inducible Murine Macrophage Nitric Oxide Synthase. J. Biol. Chem. 1991, 266, 22789-22791.
18. Martasek, P.; Liu, Q.; Liu, J.; Roman, L. J.; Gross, S. S.; Sessa, W. C.; Masters, B. S. S. Characterization of Bovine Endothelial Nitric Oxide Synthase Expressed in E. coli. Biochem. Biophys. Res. Commun. 1996, 219, 359-365.